Lattice radiation therapy for treating large tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of lattice radiation therapy (LRT) in providing better treatment outcomes for patients with bulky tumors compared to standard radiotherapy. It is a single-institution, single-arm Phase II trial that plans to enroll 37 patients, who will receive LRT in five fractions delivered every other day. The study will assess the overall response rate (ORR) at 60 days post-treatment and monitor safety and toxicity at various intervals. Additionally, a translational analysis will explore the impact of LRT on systemic immune responses.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Solid tumor malignancy with a clinical indication for radiation
* Patients must have measurable disease
* Target lesion(s) which are amenable to lattice therapy plan
* When applicable, target lesion for radiation amenable to immobilization during delivery of radiotherapy
* Age ≥18 years.
* ECOG Performance status ≤2
* Life expectancy greater than 3 months
* Women of child-bearing potential and men must agree to avoid conception via abstinence (ideal) or a method of birth control (e.g., hormonal or barrier method of birth control) prior to study entry and for at least 30 days after completion of lattice therapy administration.
* Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

* Patients receiving cytotoxic chemotherapy or known radiosensitizing agents within 5 days before or after lattice therapy.
* Patients with hematologic malignancies including lymphoma and leukemia as well as primary or metastatic central nervous system (CNS) malignancies.
* Patients with a history of conditions which predispose them to increased radiation toxicity
* Patients with known contraindications to radiation therapy
* Patients with uncontrolled intercurrent illness
* Pregnant women

Where it's running

• University of Cincinnati Medical Center
  Cincinnati, Ohio, United States Recruiting

Study contacts

• Study coordinator: UCCC Clinical Trials Office
• Email: cancer@uchealth.com
• Phone: 513-584-7698

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing a new treatment for advanced cancer using a radiolabeled drug

  This study is testing a new drug for adults with advanced cancer who have run out of other treatment options to see if it is safe and how well it works.

  Recruiting at 2 sites Phase 1/2 Spago Nanomedical AB · Adelaide, South Australia and 1 other locations · NCT06184035

• FOG-001 treatment for advanced or metastatic solid tumors

  This study is testing a new drug called FOG-001 to see if it can help people with advanced solid tumors, especially those with certain genetic changes, when traditional treatments aren't working.

  Recruiting at 32 sites Phase 1/2 Parabilis Medicines, Inc. · Phoenix, Arizona and 32 other locations · NCT05919264

• Evaluating PC14586 for advanced solid tumors with a specific mutation

  This study is testing a new oral medication called PC14586 to see if it can help people with advanced solid tumors that have a specific mutation in the TP53 gene.

  Recruiting at 71 sites Phase 1/2 PMV Pharmaceuticals, Inc · Irvine, California and 75 other locations · NCT04585750

• Dual PD1/CTLA4 immunotherapy with chemotherapy before surgery for locally advanced cervical cancer

  This study tests a combo of a PD1/CTLA4 bispecific antibody with standard chemotherapy to see if it can improve outcomes before surgery in women with locally advanced cervical cancer.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07646301

• IL-15–Enhanced NK Cell Therapy for Solid Tumors

  A first-in-human, early-phase study tests whether IL-15–enhanced engineered NK cells are safe and can show early signs of effect in adults with relapsed or metastatic solid tumors.

  Recruiting Early Phase 1 Genovn Therapeutics PTE. LTD. · Chongqing · NCT07621471

• LATTICE radiotherapy vs moderately dose-escalated palliative radiation for metastases

  This study tests whether LATTICE radiotherapy given in 5 fractions works better than a standard palliative dose for patients with metastatic cancer who have 1–2 sizable tumors.

  Recruiting Phase 2 Stanford University · Palo Alto, California · NCT07594431

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.